22:05 , May 21, 2019 |  BC Extra  |  Politics & Policy

SCOTUS decision a boon to biopharmas in failure-to-warn cases

A U.S. Supreme Court decision that remands Merck v. Albrecht back to the Court of Appeals for the Third Circuit for a judge to make a final ruling will help drug companies avoid unpredictable jury...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
23:23 , Jan 11, 2019 |  BioCentury  |  Politics, Policy & Law

Supreme Court may reset FDA-State power balance

Following oral arguments in Merck v. Albrecht on Jan. 7, the Supreme Court is pondering a decision that could reset the balance of power over drug label warnings between FDA and state courts. The outcome...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
02:59 , May 5, 2018 |  BioCentury  |  Strategy

Thinking globally, acting locally

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s...
16:31 , May 4, 2018 |  BioCentury  |  Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
22:48 , May 3, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Sangamo

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said CEO Milind Deshpande will step down. He will be succeeded by President and COO Joseph Truitt. Sangamo Therapeutics Inc. (NASDAQ:SGMO) said SVP and CBO Curt Herberts, III...
23:35 , May 1, 2018 |  BC Extra  |  Company News

Pfizer China GM Wu jumps to BeiGene

BeiGene Ltd. (NASDAQ:BGNE) hired Xiaobing Wu as general manager of China and president. He joins the Chinese bellwether from Pfizer Inc. (NYSE:PFE), where he was the long-serving greater China regional president and country manager for...
00:00 , Apr 22, 2017 |  BioCentury  |  Finance

Buying local

CanSino Biologics Inc. ’s investors are hoping a $65 million venture round will be enough to help the company launch a trio of products by 2019 to tap China’s growing demand for vaccines. Future Industry...